Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout

Apogee Therapeutics Inc. (NASDAQ:APGE) shares are up during Monday’s premarket session following the announcement of 52-week data from the Phase 2 APEX trial of zumilokibart (APG777), a potential treatment for moderate-to-severe atopic dermatitis. Durable Efficacy Across Extended Dosing Intervals The data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-month dosing regimens, with 75% and 85% of patients maintaining EASI-75, respectively. Deepening of response was observed across all lesional and itch endpoints with both every 3- and 6- month dosing among the full population of patients initially randomized to zumilokibart Well tolerated across both dosing regimens, with a safety profile generally in line with other agents in class. Strong IL-13 Inhibition Drives Clinical Benefit The trial’s findings indicate that zumilokibart achieved over 99% inhibition of IL-13, a key cytokine in atopic dermatitis, leading to significant improvements in itch and lesion relief over time. Apogee Therapeutics Phase 3 Plans And Long-Term Commercial Outlook Management anticipates initiating Phase 3 trials later this year, with a potential commercial launch expected in 2029. In January, the Phase 1b trial of zumilokibart (APG777) in asthma patients showed robust and durable suppression of FeNO, a biomarker of Type 2 inflammation that has shown the strongest correlation with exacerbations in asthma, following a single dose. Apogee Therapeutics Technical Analysis: Momentum Strong, But Indicators Mixed The stock is currently trading 5.7% above its 20-day simple moving average (SMA) and 6.9% above its 100-day SMA, indicating strong short-term momentum. Over the past 12 months, shares have increased 61.70% and are currently positioned closer to their 52-week highs than lows. The RSI is at 39.42, which is considered neutral territory, while the MACD shows a value of -0.5074, below its signal line at 0.1401, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum. Key Resistance: $77.50 Key Support: $66.00 Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $96.40. Recent analyst moves include: Truist Securities: Initiated with Hold (Target $83.00) (Mar. 18) BTIG: Buy (Maintains Target to $137.00) (Mar. 16) RBC Capital: Sector Perform (Lowers Target to $82.00) (Mar. 3) Apogee Therapeutics Benzinga Edge Rankings Below is the Benzinga Edge scorecard for Apogee Therapeutics, highlighting its strengths and weaknesses compared to the broader market: Momentum: Strong (Score: 91.97) — Stock is outperforming the broader market. The Verdict: Apogee Therapeutics’s Benzinga Edge signal reveals a momentum-driven story, reflecting strong performance relative to the market. Investors should monitor upcoming trial results and earnings for further insights into the company’s growth trajectory. APGE Stock Price Activity: Apogee Therapeutics shares were up 13.57% at $75.00 during premarket trading on Monday, according to Benzinga Pro data. Image via Shutterstock